Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain

Evaluating Safety and QoL in Patients Treated With Etanercept: an Open Multicenter Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00195377

Enrollment

1000

Registered

2005-09-19

Start date

2003-04-30

Completion date

2006-04-30

Last updated

2009-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Psoriatic, Arthritis, Rheumatoid

Brief summary

The purpose of this study is to assess the safety of etanercept in patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) or psoriatic arthritis (PsA) in Spain

Interventions

DRUGEtanercept

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

4 Years to No maximum

Healthy volunteers

Inclusion criteria

* RA or PsA in whom DMARDs/antiTNF antibodies/anti IL1 has been insufficient or inappropriate * Children from 4 to 17 years old with JIA polyarticular

Exclusion criteria

* Clinically significant abnormal screening lab values * Patients who are planning to undergo elective surgery during the study period. * Other current autoimmune connective tissue diseases

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026